Study on Relationship Between mRNA of UrokinaseType Plasminogen Activator and Breast Cancer, Lymph Nodes Metastasis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

XIONG Jun , ZHANG Jinhui , ZHENG Qichang.

Corresponding author：

Keywords：

Urokinase-type plasminogen activator Breast cancer RT-PCR Metastasis

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【Abstract】ObjectiveTo investigate the relationship between the expression of urokinase-type plasminogen activator (uPA) mRNA and breast cancer, lymph node metastasis.
MethodsSixty patients with breast tumor were selected randomly and the expression of uPA mRNA was detected with RT-PCR. The patients were divided into benign group (18 cases) and malignant group (42 cases) which included 22 cases with lymph node metastasis and 20 cases without lymph node metastasis. The relationship between uPA mRNA expression and breast cancer, lymph node metastasis was analyzed.
ResultsAmong these 18 benign tumors, low expression of uPA mRNA was found in 2 cases and the others were negative. While in 42 cases of malignant tumor, uPA mRNA were positive in 22 cases of lymph node metastasis, 16 of which were high expression, 5 of which were moderate expression, and 1 was low expression. uPA mRNA were positive in 18 of 20 cases of nonmetastatic lymph node, 1 of which was high expression, 5 of which were moderate expression and 12 of which were low expression, the other 2 were negative expression. The expression of uPA mRNA had significant difference between benign and malignant tumors (P＜0.05). The expression in lymph node metastasis was much higher than no lymph node metastasis (P＜0.05).
ConclusionThe expression of uPA mRNA in malignant breast cancer is obviously higher than that in benign breast tumor. The expression tensity of uPA is highly relevant to lymph node metastasis in malignant breast cancer, which can provide evidence for clinical staging and therapy.

Citation： XIONG Jun,ZHANG Jinhui,ZHENG Qichang.. Study on Relationship Between mRNA of UrokinaseType Plasminogen Activator and Breast Cancer, Lymph Nodes Metastasis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2005, 12(3): 241-243. doi: Copy

1.	Harbeck N, Kates RE, Gauger K, et al. Urokinasetype plasminogen activator (uPA) and its inhibitor PAII: novel tumorderived factors with a high prognostic and predictive impact in breast cancer [Ｊ]. Thromb Haemost, 2004; 91(3)∶450.
2.	Thomssen C, Janicke F, Harbeck N. Clinical relevance of prognostic factors in axillary nodenegative breast cancer [Ｊ]. Onkologie, 2003; 26(5)∶438.
3.	李亚芬.乳腺癌肿瘤标志物的研究和临床应用进展 [Ｊ]. 中国普外基础与临床杂志， 2002; 9(5)∶298.
4.	Hsu DW, Efird JT, HedleyWhyte ET. Prognostic role of urokinasetype plasminogen activator in human gliomas [Ｊ]. Am J Pathol, 1995; 147(1)∶114.
5.	熊俊，郑启昌，宋自芳. 尿激酶型纤溶酶原激活剂mRNA在胃癌组织中的表达及其意义 [Ｊ]. 中国普外基础与临床杂志， 2004; 11(2)∶116.
6.	Zemzoum I, Kates RE, Ross JS, et al. Invasion factors uPA/PAI1 and HER2 status provide independent and complementary information on patient outcome in nodenegative breast cancer [Ｊ]. J Clin Oncol, 2003; 21(6)∶1022.
7.	Guo Y, Pakneshan P, Gladu J, et al. Regulation of DNA methylation in human breast cancer. Effect on the urokinasetype plasminogen activator gene production and tumor invasion [Ｊ]. J Biol Chem, 2002; 277(44)∶41571.
8.	Harbeck N, Schmitt M, Kates RE, et al. Clinical utility of urokinasetype plasminogen activator and plasminogen activator inhibitor1 determination in primary breast cancer tissue for individualized therapy concepts [Ｊ]. Clin Breast Cancer, 2002; 3(3)∶196.
9.	Hemsen A, Riethdorf L, Brunner N, et al. Comparative evaluation of urokinasetype plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells [Ｊ]. Int J Cancer, 2003; 107(6)∶903.
10.	Qin W, Zhu W, WagnerMann C, et al. Nipple aspirate fluid expression of urokinasetype plasminogen activator, plasminogen activator inhibitor1, and urokinasetype plasminogen activator receptor predicts breast cancer diagnosis and advanced disease [Ｊ]. Ann Surg Oncol, 2003; 10(8)∶948.
11.	Qin W, Zhu W, WagnerMann C, et al. Association of uPA, PAT1, and uPAR in nipple aspirate fluid (NAF) with breast cancer [Ｊ]. Cancer J, 2003; 9(4)∶293.
12.	Manders P, TjanHeijnen VC, Span PN, et al. Predictive impact of urokinasetype plasminogen activator: plasminogen activator inhibitor type1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer [Ｊ]. Cancer Res, 2004; 64(2)∶659.
13.	Harbeck N, Kates RE, Look MP, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified highrisk according to urokinasetype plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3 424) [Ｊ]. Cancer Res, 2002; 62(16)∶4617.

1. Harbeck N, Kates RE, Gauger K, et al. Urokinasetype plasminogen activator (uPA) and its inhibitor PAII: novel tumorderived factors with a high prognostic and predictive impact in breast cancer [Ｊ]. Thromb Haemost, 2004; 91(3)∶450.
2. Thomssen C, Janicke F, Harbeck N. Clinical relevance of prognostic factors in axillary nodenegative breast cancer [Ｊ]. Onkologie, 2003; 26(5)∶438.
3. 李亚芬.乳腺癌肿瘤标志物的研究和临床应用进展 [Ｊ]. 中国普外基础与临床杂志， 2002; 9(5)∶298.
4. Hsu DW, Efird JT, HedleyWhyte ET. Prognostic role of urokinasetype plasminogen activator in human gliomas [Ｊ]. Am J Pathol, 1995; 147(1)∶114.
5. 熊俊，郑启昌，宋自芳. 尿激酶型纤溶酶原激活剂mRNA在胃癌组织中的表达及其意义 [Ｊ]. 中国普外基础与临床杂志， 2004; 11(2)∶116.
6. Zemzoum I, Kates RE, Ross JS, et al. Invasion factors uPA/PAI1 and HER2 status provide independent and complementary information on patient outcome in nodenegative breast cancer [Ｊ]. J Clin Oncol, 2003; 21(6)∶1022.
7. Guo Y, Pakneshan P, Gladu J, et al. Regulation of DNA methylation in human breast cancer. Effect on the urokinasetype plasminogen activator gene production and tumor invasion [Ｊ]. J Biol Chem, 2002; 277(44)∶41571.
8. Harbeck N, Schmitt M, Kates RE, et al. Clinical utility of urokinasetype plasminogen activator and plasminogen activator inhibitor1 determination in primary breast cancer tissue for individualized therapy concepts [Ｊ]. Clin Breast Cancer, 2002; 3(3)∶196.
9. Hemsen A, Riethdorf L, Brunner N, et al. Comparative evaluation of urokinasetype plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells [Ｊ]. Int J Cancer, 2003; 107(6)∶903.
10. Qin W, Zhu W, WagnerMann C, et al. Nipple aspirate fluid expression of urokinasetype plasminogen activator, plasminogen activator inhibitor1, and urokinasetype plasminogen activator receptor predicts breast cancer diagnosis and advanced disease [Ｊ]. Ann Surg Oncol, 2003; 10(8)∶948.
11. Qin W, Zhu W, WagnerMann C, et al. Association of uPA, PAT1, and uPAR in nipple aspirate fluid (NAF) with breast cancer [Ｊ]. Cancer J, 2003; 9(4)∶293.
12. Manders P, TjanHeijnen VC, Span PN, et al. Predictive impact of urokinasetype plasminogen activator: plasminogen activator inhibitor type1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer [Ｊ]. Cancer Res, 2004; 64(2)∶659.
13. Harbeck N, Kates RE, Look MP, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified highrisk according to urokinasetype plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3 424) [Ｊ]. Cancer Res, 2002; 62(16)∶4617.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Study on Relationship Between mRNA of UrokinaseType Plasminogen Activator and Breast Cancer, Lymph Nodes Metastasis

Abstract Full text Figures/Tables Video References Cited by

Format

Content